Abstract
Phase 1b/2 study of combination <sup>177</sup>Lu girentuximab plus cabozantinib and nivolumab in treatment naive patients with advanced clear cell RCC.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
